Advertisement
UK markets close in 5 hours 56 minutes

  • FTSE 100

    8,048.35
    +24.48 (+0.31%)
     

  • FTSE 250

    19,678.55
    +79.16 (+0.40%)
     

  • AIM

    751.78
    +2.60 (+0.35%)
     

  • GBP/EUR

    1.1587
    -0.0002 (-0.02%)
     

  • GBP/USD

    1.2357
    +0.0007 (+0.06%)
     

  • Bitcoin GBP

    53,627.19
    +208.03 (+0.39%)
     

  • CMC Crypto 200

    1,423.09
    +8.33 (+0.59%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.21
    +0.31 (+0.38%)
     

  • GOLD FUTURES

    2,308.90
    -37.50 (-1.60%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    17,976.39
    +115.59 (+0.65%)
     

  • CAC 40

    8,068.93
    +28.57 (+0.36%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Sanofi deepens cancer drive with $1.2 bln of deals, Innate jumps

Reuters - UK Focus

(Adds details on deals, Innate Pharma (Swiss: IPH.SW - news) shares)

PARIS, Jan 11 (Reuters) - Sanofi (NasdaqGM: GCVRZ - news) boosted its presence in cancer research on Monday by signing two deals with biotech companies worth up to $1.2 billion, as the French drugmaker plays catch-up with rivals in the hot research field.

Shares (Berlin: DI6.BE - news) in French biotech group Innate Pharma, one of the partners, jumped 15 percent on the news.

Switzerland's Novartis (LSE: 0QLR.L - news) also announced a deal with U.S (Other OTC: UBGXF - news) .-based Surface Oncology to increase its immuno-oncology portfolio, although it did not give financial terms.

ADVERTISEMENT

Scientific advances in understanding cancer have prompted a flood of pharmaceutical investment in research in recent years, with most excitement surrounding treatments that help the immune system fight tumours.

Bristol-Myers Squibb, Merck (Other OTC: MKGAF - news) , Roche and AstraZeneca (NYSE: AZN - news) are currently leading the pack in such immuno-oncology, but other firms are looking for promising opportunities.

Under the new deal with Innate Pharma, worth up to 400 million euros ($436 million) to the Marseilles-based biotech group, Sanofi will get access to new technology to develop so-called bispecific antibodies to fight cancer.

The hope is that the new approach will focus the immune system to kill cancer cells more effectively by engaging natural killer cells.

Separately, Sanofi is also extending an existing partnership with unlisted Warp Drive Bio with $750 million in new funding from the drugmaker.

Under the deal, Warp Drive will lead joint research on new cancer drugs, while Sanofi will be the leader in a collaboration to find new antibiotics, the companies said in a joint statement.

Sanofi has been a major backer of privately held Warp Drive since its creation in 2012. ($1 = 0.9170 euros) (Reporting by Laurence Frost and Ben Hirschler; Editing by James Regan and Adrian Croft)